Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monica Margoni

Showing results (11-20 of 78) with videos related to

Pageof 8
Sort By:
Expert Review of Neurotherapeutics|April 11, 2022
Pediatric multiple sclerosis: developments in timely diagnosis and prognosticationMonica Margoni, Paolo Preziosa, Maria A Rocca, et al.
Translational Psychiatry|July 19, 2023
Depressive symptoms, anxiety and cognitive impairment: emerging evidence in multiple sclerosisMonica Margoni, Paolo Preziosa, Maria A Rocca, et al.
Neuroimaging Clinics of North America|June 28, 2024
Diagnostic Criteria for Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, and Myelin Oligodendrocyte Glycoprotein-immunoglobulin G-associated DiseaseMassimo Filippi, Paolo Preziosa, Monica Margoni, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|June 6, 2022
Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid BiomarkersMonica Margoni, Paolo Preziosa, Paola Tortorella, et al.
Journal of the Neurological Sciences|November 18, 2018
A new Italian family with HTRA1 mutation associated with autosomal-dominant variant of CARASIL: Are we pointing towards a disease spectrum?Silvia Favaretto, Monica Margoni, Leonardo Salviati, et al.
Current Neuropharmacology|August 28, 2025
Pharmacodynamics and Pharmacokinetics of Ublituximab Compared with Other Anti-Cd20 Monoclonal Antibodies for Multiple Sclerosis TreatmentMonica Margoni, Luca Battistini, Diego Centonze, et al.
Journal of the Neurological Sciences|February 2, 2019
Isolated choroid plexus involvement in a case of granulomatosis with polyangiitis negative for antineutrophil cytoplasmic antibodies (ANCA)Monica Margoni, Mattia Barbareschi, Umberto Rozzanigo, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|June 3, 2019
Idiopathic hypertrophic cranial pachymeningitis as a rare cause of status epilepticusMonica Margoni, Mattia Barbareschi, Umberto Rozzanigo, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|September 27, 2019
Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosisMonica Margoni, Francesca Rinaldi, Silvia Miante, et al.
Journal of Neurology|September 29, 2019
No evidence of disease activity including cognition (NEDA-3 plus) in naïve pediatric multiple sclerosis patients treated with natalizumabMonica Margoni, Francesca Rinaldi, Alice Riccardi, et al.
Pageof 8

Showing results (11-20 of 78) with videos related to

Sort By:
Pageof 8
Expert Review of Neurotherapeutics|April 11, 2022
Pediatric multiple sclerosis: developments in timely diagnosis and prognosticationMonica Margoni, Paolo Preziosa, Maria A Rocca, et al.
Translational Psychiatry|July 19, 2023
Depressive symptoms, anxiety and cognitive impairment: emerging evidence in multiple sclerosisMonica Margoni, Paolo Preziosa, Maria A Rocca, et al.
Neuroimaging Clinics of North America|June 28, 2024
Diagnostic Criteria for Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, and Myelin Oligodendrocyte Glycoprotein-immunoglobulin G-associated DiseaseMassimo Filippi, Paolo Preziosa, Monica Margoni, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|June 6, 2022
Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid BiomarkersMonica Margoni, Paolo Preziosa, Paola Tortorella, et al.
Journal of the Neurological Sciences|November 18, 2018
A new Italian family with HTRA1 mutation associated with autosomal-dominant variant of CARASIL: Are we pointing towards a disease spectrum?Silvia Favaretto, Monica Margoni, Leonardo Salviati, et al.
Current Neuropharmacology|August 28, 2025
Pharmacodynamics and Pharmacokinetics of Ublituximab Compared with Other Anti-Cd20 Monoclonal Antibodies for Multiple Sclerosis TreatmentMonica Margoni, Luca Battistini, Diego Centonze, et al.
Journal of the Neurological Sciences|February 2, 2019
Isolated choroid plexus involvement in a case of granulomatosis with polyangiitis negative for antineutrophil cytoplasmic antibodies (ANCA)Monica Margoni, Mattia Barbareschi, Umberto Rozzanigo, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|June 3, 2019
Idiopathic hypertrophic cranial pachymeningitis as a rare cause of status epilepticusMonica Margoni, Mattia Barbareschi, Umberto Rozzanigo, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|September 27, 2019
Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosisMonica Margoni, Francesca Rinaldi, Silvia Miante, et al.
Journal of Neurology|September 29, 2019
No evidence of disease activity including cognition (NEDA-3 plus) in naïve pediatric multiple sclerosis patients treated with natalizumabMonica Margoni, Francesca Rinaldi, Alice Riccardi, et al.
Pageof 8